Gold bars to be exempt from tariffs, White House clarifies
Investing.com - Goldman Sachs upgraded Cushman & Wakefield (NYSE:CWK) from Sell to Buy and set a price target of $17.50, citing improved performance in several key areas.
The upgrade follows Cushman & Wakefield’s second-quarter 2025 results and comes after the stock underperformed both its peers and the S&P 500 by approximately 16% since Goldman Sachs added it to its Sell list on December 6, 2024.
Goldman Sachs highlighted three main factors behind the rating change: meaningful improvement in services segment revenue growth, particularly in EMEA due to large project management wins; enhanced profitability of EMEA services contracts following restructuring actions; and steady progress on the company’s capital allocation strategy of reducing leverage while reinvesting in the business. With a current market capitalization of $3.1 billion and an overall Financial Health score of GOOD from InvestingPro, the company appears well-positioned for future growth.
The investment bank’s analysis of Cushman & Wakefield’s EMEA margins indicates the company is beginning to realize significant margin benefits from its services contract restructuring, which Goldman Sachs believes is not yet reflected in consensus estimates for future quarters.
Goldman Sachs also noted that Cushman & Wakefield’s second-quarter 2025 Americas capital markets results suggest its reinvestment initiatives are helping reverse previous market share losses, with potential benefits in the second half of 2025 from easier year-over-year capital markets comparisons due to its strong small deals franchise.
In other recent news, Cushman & Wakefield reported strong financial results for the second quarter of 2025, exceeding Wall Street expectations. The company’s earnings per share were $0.30, surpassing the forecasted $0.22, which represents a 36.36% surprise. Revenue reached $2.48 billion, beating the expected $2.38 billion by 4.2%. Following these results, Citizens JMP raised its price target for the company to $16 from $15, maintaining a Market Outperform rating. Raymond (NSE:RYMD) James also increased its price target to $17 from $15, citing the company’s improved free cash flow generation and reduced leverage. The firm demonstrated 7% organic revenue growth and raised its full-year outlook, highlighting its business momentum and operating efficiencies. These developments reflect Cushman & Wakefield’s ongoing efforts to strengthen its financial position and performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.